Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 15/20 | 0.55 |
| ▸ | MCL1 | Q07820 | 2/20 | 0.45 |
| ▸ | ACLY | P53396 | 1/20 | 0.45 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6750603 | 0.90 | CCR9 (0.54) | CCR2MCL1 | |
| SCHEMBL15416321 | 0.85 | NOD2 (0.47) | CCR2 | |
| SCHEMBL4372812 | 0.84 | CCR2 (0.60) | CCR2MCL1ABCB11 | |
| SCHEMBL23330647 | 0.82 | ACLY (0.41) | CCR2ACLY | |
| SCHEMBL15685313 | 0.82 | TDP1 (0.41) | CCR2 | |
| SCHEMBL6750553 | 0.82 | CCR9 (0.56) | CCR2 | |
| SCHEMBL15416658 | 0.82 | ACLY (0.47) | CCR2ACLY | |
| SCHEMBL16235858 | 0.82 | CCR2 (0.59) | CCR2MCL1ABCB11 | |
| SCHEMBL16235848 | 0.82 | NOD2 (0.46) | CCR2 | |
| SCHEMBL8687383 | 0.81 | CCR2 (0.62) | CCR2ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-04-04 | — | — | US | claimed |
| EP-4051662-B1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL}METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-07 | — | — | EP | claimed |
| CN-114630828-B | Synthesis of RSV inhibition compound | 杨森科学爱尔兰无限公司 | 2023-10-31 | — | — | CN | claimed |
| CN-114630828-A | Synthesis of 3- ({ 5-chloro-1- [3- (methylsulfonyl) propyl ] -1H-indol-2-yl } methyl) -1- (2,2, 2-trifluoroethyl) -1, 3-dihydro-2H-imidazo [4,5-c ] pyridin-2-one | 杨森科学爱尔兰无限公司 | 2022-06-14 | — | — | CN | claimed |
| WO-2021083998-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-06 | — | — | WO | claimed |
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JOHNSON & JOHNSON (CHINA) INVESTMENT LTD. (CN) | 2024-04-04 | — | — | US | disclosed |
| EP-4051662-B1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL}METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | JANSSEN SCIENCES IRELAND UNLIMITED CO (IE) | 2024-02-07 | — | — | EP | disclosed |
| CN-114630828-B | Synthesis of RSV inhibition compound | 杨森科学爱尔兰无限公司 | 2023-10-31 | — | — | CN | disclosed |
| CN-114630828-A | Synthesis of 3- ({ 5-chloro-1- [3- (methylsulfonyl) propyl ] -1H-indol-2-yl } methyl) -1- (2,2, 2-trifluoroethyl) -1, 3-dihydro-2H-imidazo [4,5-c ] pyridin-2-one | 杨森科学爱尔兰无限公司 | 2022-06-14 | — | — | CN | disclosed |
| WO-2021083998-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-06 | — | — | WO | disclosed |
| WO-2021083998-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2 YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | Janssen Sciences Ireland Unlimited Company (IE) | 2021-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240109894-A1 | SYNTHESIS OF 3-({5-CHLORO-1-[3-(METHYLSULFONYL)PROPYL]-1H-INDOL-2-YL} METHYL)-1-(2,2,2-TRIFLUOROETHYL)-1,3-DIHYDRO-2H-IMIDAZO[4,5-C]PYRIDIN-2-ONE | HTR3C, MECP2, CDK2 | CCR2 501/4885MCL1 1795/4885ACLY 3884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.